List of Excipients in Branded Drug MYAMBUTOL

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
A-S Medication Solutions	MYAMBUTOL	ethambutol hydrochloride	50090-2607	GELATIN
A-S Medication Solutions	MYAMBUTOL	ethambutol hydrochloride	50090-2607	MAGNESIUM STEARATE
A-S Medication Solutions	MYAMBUTOL	ethambutol hydrochloride	50090-2607	SORBITOL
A-S Medication Solutions	MYAMBUTOL	ethambutol hydrochloride	50090-2607	STEARIC ACID

MYAMBUTOL Excipient Strategy and Commercial Opportunities for Ethambutol Hydrochloride

Last updated: September 5, 2026

Myambutol is the branded form of ethambutol hydrochloride, an established antituberculosis drug with limited patent barriers and substantial generic competition. The principal commercial opportunities are not in new-molecule exclusivity. They are in differentiated oral dosage forms, pediatric dispersible tablets, fixed-dose combinations, taste masking, supply reliability, and excipient systems that improve manufacturability without changing ethambutol exposure.

Ethambutol has a high-risk safety characteristic: dose-related optic toxicity. Any formulation strategy must preserve dose accuracy, dissolution, stability, and labeling controls. Excipient changes that alter absorption, tablet identification, or dose administration can create regulatory and clinical risks disproportionate to the low cost of the active ingredient.

What is Myambutol and how is ethambutol used?

Myambutol contains ethambutol hydrochloride, a bacteriostatic antimycobacterial agent used as part of combination therapy for tuberculosis. It is generally administered with other antituberculosis drugs to reduce the risk of resistance. Ethambutol is also used in some nontuberculous mycobacterial disease regimens under specialist supervision.

The commercial product is an immediate-release oral tablet. Typical strengths include 100 mg and 400 mg tablets, although market availability varies by jurisdiction. Dosing is weight-based and may change during treatment. The label emphasizes baseline and periodic visual assessment because ethambutol can cause optic neuritis and changes in visual acuity or color discrimination.[1]

Attribute	Myambutol and ethambutol hydrochloride
Active ingredient	Ethambutol hydrochloride
Therapeutic class	Antimycobacterial
Primary use	Combination treatment for tuberculosis
Common dosage form	Immediate-release tablet
Key dose variable	Patient body weight and renal function
Principal safety issue	Optic neuritis and visual impairment
Generic competition	Established in major markets
Biosimilar exposure	None; ethambutol is a small molecule
Main formulation opportunity	Pediatric, dispersible, fixed-dose and adherence-oriented products

What excipients are used in Myambutol tablets?

The excipient profile depends on the specific manufacturer, market, strength, and current approved labeling. Historical and current ethambutol tablet formulations use conventional solid-dose excipients such as diluents, binders, disintegrants, lubricants, glidants, and colorants.

Potential excipient classes include:

Excipient function	Candidate materials	Commercial purpose
Diluent	Lactose, microcrystalline cellulose, starch, mannitol	Tablet mass, compressibility, dose uniformity
Binder	Povidone, pregelatinized starch, hydroxypropyl cellulose	Granule strength and tablet integrity
Disintegrant	Croscarmellose sodium, sodium starch glycolate, crospovidone	Rapid tablet breakup
Lubricant	Magnesium stearate, stearic acid, sodium stearyl fumarate	Ejection from tooling and manufacturing control
Glidant	Colloidal silicon dioxide, talc	Powder flow and die filling
Taste modifier	Sweeteners, flavors, ion-exchange systems, polymer coatings	Pediatric acceptability
Film coating	Hypromellose, polyethylene glycol, titanium dioxide or approved alternatives	Swallowability, identification and taste control
Moisture control	Low-moisture excipient grades, protective packaging	Stability and shelf life

A sponsor must treat the inactive-ingredient list as product-specific. The brand label, generic labels, DailyMed records, and local regulatory filings should be reconciled before making a formulation or freedom-to-operate decision.[1,2]

Which excipient attributes matter most for ethambutol tablets?

Ethambutol tablet development is relatively straightforward from a dosage-form perspective, but several attributes are commercially important:

1. Dose uniformity. Low-strength tablets contain a small amount of active relative to excipients. Segregation, poor flow, or inadequate granulation can affect content uniformity.
2. Rapid dissolution. Ethambutol is used in multidrug regimens. A formulation should avoid unnecessary release-rate modification unless supported by bioequivalence data.
3. Mechanical strength. Tablets must withstand bulk packaging, global distribution, and repeated handling.
4. Moisture robustness. Tropical markets and public-health procurement can expose products to high humidity and variable storage conditions.
5. Swallowability. Treatment courses are long, and tablet burden can reduce adherence.
6. Patient acceptability. Bitter taste is a major barrier for pediatric or dispersible products.
7. Visual differentiation. Different strengths should be clearly distinguishable to reduce dosing errors.

What excipient strategy is most attractive for Myambutol?

The highest-value strategy is a platform approach that supports three products: an adult immediate-release tablet, a pediatric dispersible tablet, and a fixed-dose combination.

Adult immediate-release tablets

For standard adult tablets, the preferred development path is a conventional, low-cost formulation using well-characterized excipients with broad regulatory acceptance. Direct compression may reduce processing costs if powder flow and content uniformity are adequate. Wet or dry granulation may be preferable where the active ingredient has poor flow, low-dose distribution problems, or inadequate compactability.

The commercial objective is usually not a novel release profile. It is a robust product that:

• meets dissolution requirements across multiple batches;
• remains stable under Zone IVb conditions where relevant;
• supports high-speed compression;
• minimizes tablet weight;
• uses globally available excipient grades; and
• avoids unnecessary formulation complexity.

A lactose-free version may have value in selected markets, but lactose is not inherently unsuitable for most patients. Replacing lactose with mannitol or microcrystalline cellulose can increase cost, tablet size, or compression risk. The change should be justified by a defined market requirement rather than positioned as a generic safety advantage.

Pediatric dispersible tablets

Pediatric tuberculosis treatment is the strongest excipient-led opportunity. The World Health Organization has emphasized child-friendly formulations, including dispersible tablets for pediatric antituberculosis regimens.[3]

A pediatric ethambutol product should address:

• rapid dispersion in a small volume of water;
• acceptable taste;
• accurate administration by caregivers;
• low tablet burden;
• compatibility with fixed-dose combination therapy; and
• stability in hot and humid environments.

Taste masking is the central technical problem. Ethambutol can produce an unpleasant taste, and dispersible tablets expose the drug to the oral cavity. Candidate approaches include polymer film coating, multiparticulate coating, ion-exchange resins, complexation, sweetener systems, and flavor systems. Each approach affects tablet size, dissolution, manufacturability, and regulatory comparability.

A taste-masking system that delays dissolution in the stomach or produces a measurable pharmacokinetic difference may require more extensive development than a conventional immediate-release product. The preferred design is a formulation that reduces oral bitterness while preserving rapid gastrointestinal release.

Fixed-dose combinations

Fixed-dose combination products are commercially relevant because tuberculosis treatment depends on multiple drugs. Ethambutol is commonly combined with rifampicin, isoniazid, and pyrazinamide in public-health regimens.

The excipient strategy becomes more difficult because the formulation must manage:

• different drug loadings;
• different compression properties;
• chemical compatibility;
• moisture sensitivity;
• dissolution of each active ingredient;
• color and tablet identification; and
• the risk that one active affects another during storage.

A combination product can use a single-layer tablet, bilayer tablet, multilayer tablet, or separate dispersible units. Bilayer and multilayer systems may provide better control of incompatible actives but increase equipment and process-validation requirements.

The commercial advantage is stronger than for a standalone ethambutol tablet because procurement agencies often prefer regimen simplification. The primary barriers are clinical development, comparative dissolution, stability, and regulatory requirements for the full combination rather than patent protection.

What formulation patents could protect an ethambutol product?

A new patent is unlikely to protect ethambutol itself because the compound is an established generic active. Patentable subject matter could instead include:

• a specific taste-masking composition;
• a pediatric dispersible tablet;
• a defined excipient ratio;
• a multilayer or bilayer fixed-dose tablet;
• a moisture-resistant coating;
• a controlled-release formulation;
• a novel salt, co-crystal, or particle-size distribution;
• a manufacturing process that improves content uniformity; or
• a packaging and stability system linked to a defined formulation.

Patent strength would depend on claim breadth, unexpected technical effects, enablement, and the availability of design-around options. A narrow claim covering a particular sweetener, polymer, or lubricant ratio would usually be easier to design around than a claim tied to a measurable performance profile, such as rapid dispersion, defined dissolution, and sustained taste masking.

How strong is the patent estate for Myambutol?

The core patent estate for ethambutol and the original Myambutol product is effectively a legacy estate. The active ingredient is long off-patent, and standard immediate-release tablets are exposed to generic competition.

The more relevant question is whether a specific modern formulation has secondary patents. Those patents would protect only the claimed formulation, manufacturing process, delivery system, or combination. They would not generally prevent a conventional ethambutol hydrochloride tablet from entering the market.

IP category	Commercial relevance
Original ethambutol compound patents	Expired or no longer commercially controlling
Standard immediate-release tablet	Weak patent position
Pediatric dispersible formulation	Potentially protectable
Taste-masking technology	Potentially protectable
Fixed-dose combination	Potentially protectable, depending on claims
Manufacturing process	Potentially protectable if technically specific
Packaging and stability system	Potentially protectable in narrow circumstances
Trademark rights in Myambutol	Separate from active-ingredient exclusivity

What is the FDA regulatory status of Myambutol?

Ethambutol hydrochloride is an FDA-approved antituberculosis active ingredient. The U.S. product is regulated as a prescription drug, and approved labeling includes warnings concerning visual toxicity and use in patients with impaired renal function.[1]

A company seeking to market a generic tablet would generally rely on an abbreviated new drug application pathway if the reference product and dosage form are eligible. The development program would focus on pharmaceutical equivalence, bioequivalence, manufacturing controls, dissolution, stability, labeling, and facility compliance.

For a new pediatric dispersible product or a materially different dosage form, the pathway may require a more extensive regulatory package. A product that changes dosing instructions, administration method, or combination composition may not fit the simplest generic strategy.

What is the Orange Book status of Myambutol?

The Orange Book is the relevant U.S. source for listed patents and regulatory exclusivity associated with approved drug products. A legacy ethambutol product generally should not be assumed to have active Orange Book patent protection merely because the Myambutol trademark remains recognized.

For commercial diligence, the applicable question is whether the current reference listing has:

• active listed patents;
• pediatric exclusivity;
• orphan exclusivity;
• a current reference product designation;
• an approved dosage form that matches the proposed generic; and
• an active marketing status.

The Orange Book and FDA Drugs@FDA records should be reviewed for the exact reference product and NDA status because products can be discontinued, transferred, or listed under different marketing arrangements.[4,5]

Are Paragraph IV challenges relevant to Myambutol?

Paragraph IV litigation risk is limited for a conventional ethambutol tablet if no unexpired Orange Book patent is listed against the relevant reference product. A Paragraph IV certification becomes relevant only when an applicant addresses an unexpired listed patent.

For a new formulation, the litigation risk would shift from the core ethambutol molecule to secondary patents covering:

• taste masking;
• dispersible technology;
• fixed-dose combinations;
• release characteristics;
• tablet architecture; or
• manufacturing processes.

A generic applicant can often reduce risk by using a different excipient system, dosage form, coating process, or tablet structure. The strength of any patent challenge would depend on claim construction, prosecution history, prior art, and evidence that the alternative formulation practices the asserted claims.

When does Myambutol lose exclusivity?

The core molecular and conventional formulation exclusivity for ethambutol has already expired. Myambutol therefore competes primarily on brand recognition, supply continuity, physician familiarity, procurement status, and distribution.

There is no biosimilar exclusivity issue because ethambutol is a small-molecule drug, not a biologic. There is also no meaningful commercial protection from the original active-ingredient patent estate in the United States or other mature generic markets.

The principal timing issue is regulatory and commercial rather than patent-based:

Event	Commercial impact
Original molecule and product patents expire	Generic entry becomes possible
ANDA approvals increase	Price competition intensifies
Public-health tenders open	Volume may increase while price declines
Pediatric or dispersible product launches	Differentiated pricing becomes possible
Fixed-dose combination qualification	Procurement access may improve
Supply interruption by incumbent suppliers	New manufacturers gain share opportunity

Which companies are challenging or competing with Myambutol?

The competitive field is primarily composed of generic manufacturers and public-health suppliers. Competition varies by country and procurement channel. Relevant competitors may include manufacturers of ethambutol hydrochloride tablets and combination tuberculosis products, including large generic companies, regional manufacturers, and suppliers qualified for public-health tenders.

The commercial analysis should distinguish among:

• U.S. ANDA suppliers;
• European and other national generic manufacturers;
• WHO-prequalified tuberculosis suppliers;
• government procurement contractors;
• fixed-dose combination manufacturers; and
• branded or originator-linked distributors.

Brand-level market share is often less important than tender eligibility, regulatory approvals, production capacity, and ability to supply complete tuberculosis regimens.

What commercial opportunities exist for ethambutol excipient innovation?

Pediatric tuberculosis products

This is the clearest opportunity. A palatable dispersible ethambutol product can address adherence and administration problems that standard tablets do not solve. The strongest commercial proposition combines:

• acceptable taste;
• low tablet count;
• rapid dispersion;
• stable performance in tropical climates;
• compatibility with pediatric dosing; and
• inclusion in a broader fixed-dose regimen.

Excipient systems for global manufacturing

A formulation based on globally available excipient grades can reduce supply-chain risk. This matters in tuberculosis markets where procurement depends on predictable delivery and where manufacturing may occur across multiple regions.

A sponsor can create value through:

• dual sourcing of critical excipients;
• specification ranges that accommodate multiple suppliers;
• low-moisture formulations;
• direct compression where feasible;
• reduced dependence on specialized coating materials; and
• packaging validated for high humidity.

Fixed-dose combinations

Ethambutol can be part of a broader regimen product rather than a standalone commercial item. Combination products may achieve better procurement access and adherence, although price competition is intense.

Modified tablet identification and adherence support

Color, shape, embossing, score lines, and blister-pack design can reduce medication errors. These measures are usually weak patent assets but can improve usability and procurement differentiation.

Specialty products for renal impairment

Ethambutol dosing requires attention to renal function. A lower-strength or more flexible dosage presentation could help clinicians manage dose adjustment. The commercial opportunity is narrower and must be evaluated against the risk of dosing errors and additional regulatory requirements.

What manufacturing and IP barriers affect an ethambutol product?

The largest manufacturing barriers are generally process and quality barriers rather than active-ingredient synthesis. Important controls include:

• content uniformity at low dose;
• blend segregation;
• dissolution after scale-up;
• lubricant sensitivity;
• tablet capping and friability;
• moisture-related degradation;
• taste-masking reproducibility;
• compatibility in fixed-dose combinations; and
• stability after transport.

Manufacturing-process patents may be relevant if a supplier uses a specialized granulation, coating, particle engineering, or multilayer-tablet process. In many cases, those processes can be designed around, but a design-around may increase capital expenditure or validation burden.

Excipient sourcing can also create practical IP risk. Proprietary taste-masking systems, coated particles, co-processed excipients, and specialty dispersible platforms may be licensed rather than freely substituted. A commercial developer should separate freedom to operate for the drug product from freedom to operate for each critical excipient technology.

How does Myambutol compare with other tuberculosis drugs?

Product type	Patent barrier	Excipient challenge	Commercial opportunity
Ethambutol immediate-release tablet	Low	Standard compression and stability	Low-cost, reliable supply
Ethambutol pediatric dispersible tablet	Low to moderate	Taste masking and rapid dispersion	High relative opportunity
Ethambutol fixed-dose combination	Low to moderate	Compatibility and multi-active dissolution	High procurement relevance
Rifampicin combination	Product-specific	Moisture sensitivity and interaction control	Strong but technically demanding
Isoniazid or pyrazinamide tablet	Low	Conventional solid-dose development	Commodity competition
Long-acting or injectable tuberculosis products	Higher	Complex delivery and clinical development	More differentiated, higher investment

Ethambutol is therefore most attractive as part of a child-friendly or regimen-based product platform. A standalone adult tablet is mainly a scale, cost, and supply business.

Key Takeaways

• Myambutol is an established ethambutol hydrochloride product with no meaningful remaining core-molecule exclusivity.
• The principal commercial opportunity is formulation differentiation, not new active-ingredient patenting.
• Pediatric dispersible tablets offer the strongest excipient-led opportunity.
• Taste masking must preserve rapid release and dose predictability.
• Fixed-dose combinations can improve procurement access but create compatibility and dissolution challenges.
• Conventional adult tablets are likely to compete on cost, quality, supply continuity, and tender participation.
• Formulation patents may protect specific excipient systems, tablet architectures, manufacturing methods, or performance profiles.
• Paragraph IV risk is limited for conventional ethambutol tablets unless an unexpired listed patent covers the relevant reference product.
• Ethambutol has no biosimilar risk because it is a small molecule.
• FDA, Orange Book, DailyMed, WHO, and jurisdiction-specific product records should be used to confirm the exact reference product, inactive ingredients, listing status, and approved dosage forms.

FAQs

Can ethambutol hydrochloride be reformulated as an orally disintegrating tablet?

Yes. An orally disintegrating or rapidly dispersible tablet is technically feasible, but taste masking, dose uniformity, mechanical strength, and dissolution must be controlled. The product may require a regulatory pathway different from a conventional generic tablet.

Which excipient is best for masking ethambutol bitterness?

No single excipient is universally optimal. Polymer coating, ion-exchange resin complexation, cyclodextrin systems, sweeteners, and flavor combinations can be evaluated. The preferred system is the one that provides reliable palatability without delaying gastrointestinal release or creating stability problems.

Can a new excipient combination extend Myambutol patent protection?

A new excipient combination can support a secondary patent only if it satisfies patentability requirements and the claims cover a non-obvious technical solution. It cannot restore exclusivity to the expired ethambutol molecule itself.

Is ethambutol suitable for a once-daily modified-release product?

A modified-release product is technically possible, but its value is uncertain. Ethambutol is commonly used in combination regimens, so the release profile must remain compatible with the other drugs and with established clinical dosing. The development burden would be materially higher than for an immediate-release tablet.

What is the best commercial route for a new ethambutol product?

The strongest route is a pediatric dispersible or fixed-dose combination product designed for public-health procurement. A conventional adult tablet offers lower technical risk but is exposed to intense generic price competition.

References

1. U.S. Food and Drug Administration. (n.d.). Myambutol: Ethambutol hydrochloride prescribing information.
2. National Library of Medicine. (n.d.). DailyMed: Ethambutol hydrochloride tablet and Myambutol labeling records.
3. World Health Organization. (2022). WHO operational handbook on tuberculosis: Module 5, management of tuberculosis in children and adolescents. World Health Organization.
4. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, Orange Book.
5. U.S. Food and Drug Administration. (n.d.). Drugs@FDA: FDA-approved drugs database.